Intero Biosystems is shipping mini human intestines to drugmakers

Intero Biosystems is developing miniature human intestines that drugmakers can use to study how compounds affect the gut before clinical testing. The Denver startup’s GastroScreen platform uses stem-cell-derived intestinal organoids as a more human-relevant model to supplement animal studies and simpler cell cultures.¹²

The company describes GastroScreen as an intestinal model containing major cell types including epithelial, mesenchymal, smooth muscle, enteric nerve and endothelial cells. Intero says the organoids also show organ-wide functions such as peristalsis-like contractions, perfusable blood vessels and a responsive enteric nervous system.²

What Intero is actually selling

GastroScreen is supplied as live or frozen vials containing more than 100 viable organoids, according to Intero’s platform information. The company says the product is compatible with imaging, gene and protein expression, barrier-function assays and other functional readouts.²

TechCrunch reports that each organoid is roughly one millimetre across and that Intero ships batches of about 100 to customers in pharmaceutical, biotech, food and chemical industries. Customers can use the models as healthy intestinal tissue or induce disease-like conditions to examine how compounds affect the gut.¹

That does not make GastroScreen a replacement for clinical trials, and Intero is not claiming that it has already solved the problem of translating preclinical results into human outcomes. The company told TechCrunch that it is still building the evidence: it has shown that the model contains key gut tissues and is testing well-known drugs with documented human effects before comparing results with animal and clinical data.¹

The wider market is moving in the same direction. The U.S. Food and Drug Administration has promoted organoids, organs-on-chips and computational models as possible alternatives or complements to animal testing, while draft guidance sets out considerations for validating new approach methodologies used in regulatory submissions.¹

Intero’s near-term challenge is scale. The startup can currently produce a few thousand organoids at a time and wants to automate manufacturing to reach hundreds of thousands per batch, TechCrunch reports. Longer term, it says the same approach could support patient-specific models made from reprogrammed adult cells.¹

Our opinion

GastroScreen is interesting because it aims at the uncomfortable middle ground between a flat layer of cells and a full clinical study. A model that includes several tissue types and measurable gut functions could give researchers useful evidence earlier, especially for toxicity questions that animal models do not always predict well. But the company’s own description of its validation work is the key caveat: biological complexity is promising, not proof of superior prediction. The meaningful milestone will be reproducible head-to-head results against established animal and clinical datasets, not the visual appeal of a miniature organ.

Intero’s story is therefore less “animals are finished” and more “preclinical testing is gaining another instrument”. If manufacturing becomes reliable and independent validation supports the company’s claims, organoids could make drug development more human-relevant without pretending that one laboratory model can capture every patient.¹²